CO5570703A2 - Antagonistas de cgrp elegidos, procedimiento para su prepara cion, asi como su empleo como medicamentos - Google Patents
Antagonistas de cgrp elegidos, procedimiento para su prepara cion, asi como su empleo como medicamentosInfo
- Publication number
- CO5570703A2 CO5570703A2 CO05050510A CO05050510A CO5570703A2 CO 5570703 A2 CO5570703 A2 CO 5570703A2 CO 05050510 A CO05050510 A CO 05050510A CO 05050510 A CO05050510 A CO 05050510A CO 5570703 A2 CO5570703 A2 CO 5570703A2
- Authority
- CO
- Colombia
- Prior art keywords
- group
- alkyl group
- substituted
- ring
- nitrogen
- Prior art date
Links
- 229940127597 CGRP antagonist Drugs 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- -1 phenylsulfonylamino Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002883 imidazolyl group Chemical group 0.000 abstract 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000001544 thienyl group Chemical group 0.000 abstract 2
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical group CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 abstract 1
- LISFMEBWQUVKPJ-FOQJRBATSA-N 1H-quinolin-2-one Chemical group C1=CC=C2N[14C](=O)C=CC2=C1 LISFMEBWQUVKPJ-FOQJRBATSA-N 0.000 abstract 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
Abstract
1.- Antagonistas de CGRP de la fórmula general en la que significan A un átomo de oxígeno o azufre, un grupo fenilsulfonilamino o cianimino, X un átomo de oxígeno o azufre, un grupo imino, eventualmente sustituido con un grupo alquilo C1-6, o un grupo metileno, eventualmente sustituido con un grupo alquilo C1-6,Y y Z, independientemente uno de otro, en cada caso un grupo alquilo C1-6 de cadena lineal o ramificado, en el que cada grupo metileno puede estar sustituido con hasta 2 átomos de flúor y cada grupo metilo puede estar sustituido con hasta 3 átomos de flúor, pudiendo estar unidos entre sí los grupos alquilo precedentemente mencionados, junto con los átomos de carbono a los que están unidos, con formación de un anillo de 4 a 8 miembros, R1 un heterociclo aza, diaza, triaza, oxaza, tiaza, tiadiaza o S,S-dióxido-tiadiaza de 5 a 7 miembros, saturado, insaturado una o dos veces, estando los heterociclos precedentemente mencionados enlazados a través de un átomo de carbono o nitrógeno, conteniendo uno o dos grupos carbonilo o tiocarbonilo contiguos a un átomo de nitrógeno, pudiendo estar sustituidos en uno de los átomos de nitrógeno con un grupo alquilo, pudiendo estar sustituidos en uno o en dos átomos de carbono con un grupo alquilo, con un grupo fenilo, fenilmetilo, naftilo, biofenililo, piridinilo, diazinilo, furilo, tienilo, pirrolilo, 1,3-oxazolilo, 1,3-tiazolilo, isoxazolilo, pirazolilo, 1-metilpirazolilo, imidazolilo o 1-metilimidazolilo, pudiendo los sustituyentes ser iguales o diferentes, y pudiendo estar condensado un doble enlace olefínico de uno de los heterociclos insaturados precedentemente mencionados con un anillo de fenilo, naftilo, piridina, diazina, 1,3-oxazol, tienilo, furano, tiazol, pirrol, N-metilpirrol o quinolina, con un anillo de 1H-quinolin-2-ona, eventualmente sustituido en el átomo de nitrógeno con un grupo alquilo, o con un anillo de imidazol o ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10250082A DE10250082A1 (de) | 2002-10-25 | 2002-10-25 | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5570703A2 true CO5570703A2 (es) | 2005-10-31 |
Family
ID=32103088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05050510A CO5570703A2 (es) | 2002-10-25 | 2005-05-24 | Antagonistas de cgrp elegidos, procedimiento para su prepara cion, asi como su empleo como medicamentos |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20040132716A1 (es) |
| EP (1) | EP1558601A1 (es) |
| JP (1) | JP4435687B2 (es) |
| KR (1) | KR20050083821A (es) |
| CN (1) | CN1708492A (es) |
| AR (1) | AR043056A1 (es) |
| AU (1) | AU2003276157A1 (es) |
| BR (1) | BR0315642A (es) |
| CA (1) | CA2503462A1 (es) |
| CO (1) | CO5570703A2 (es) |
| DE (1) | DE10250082A1 (es) |
| EA (1) | EA009984B1 (es) |
| EC (1) | ECSP055746A (es) |
| HR (1) | HRP20050365A2 (es) |
| ME (1) | MEP51408A (es) |
| MX (1) | MXPA05004188A (es) |
| NO (1) | NO20052493D0 (es) |
| PE (1) | PE20040780A1 (es) |
| PL (1) | PL376373A1 (es) |
| RS (1) | RS20050329A (es) |
| TW (1) | TW200427681A (es) |
| UA (1) | UA82206C2 (es) |
| UY (1) | UY28040A1 (es) |
| WO (1) | WO2004037811A1 (es) |
| ZA (1) | ZA200502247B (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10163595A1 (de) * | 2001-12-21 | 2003-08-07 | Gruenenthal Gmbh | In 3-Position heterocyclisch substituierte Piperidin-2,6-dione |
| US7220862B2 (en) * | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| AU2003237255B8 (en) * | 2002-06-05 | 2010-01-07 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| US7842808B2 (en) * | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
| US7595312B2 (en) * | 2002-10-25 | 2009-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
| AR046787A1 (es) * | 2003-12-05 | 2005-12-21 | Bristol Myers Squibb Co | Agentes antimigrana heterociclicos |
| DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| TW200533398A (en) * | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| DE102004018795A1 (de) * | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US20050282857A1 (en) * | 2004-04-15 | 2005-12-22 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| US7696195B2 (en) | 2004-04-22 | 2010-04-13 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| US20050267141A1 (en) * | 2004-05-28 | 2005-12-01 | Phytogen Life Sciences Inc. | Process to prepare camptothecin derivatives |
| JP2008515895A (ja) * | 2004-10-07 | 2008-05-15 | メルク エンド カムパニー インコーポレーテッド | Ｃｇｒｐ受容体拮抗薬 |
| CN101039718A (zh) * | 2004-10-14 | 2007-09-19 | 默克公司 | Cgrp受体拮抗剂 |
| US7745427B2 (en) * | 2004-10-22 | 2010-06-29 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| US7384930B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7384931B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7449586B2 (en) * | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
| DE102004063752A1 (de) * | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen |
| DE102004063753A1 (de) * | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne |
| DE102004063755A1 (de) * | 2004-12-29 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs |
| EP1770091A1 (de) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7491717B2 (en) | 2005-03-23 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| CN101146799A (zh) * | 2005-03-23 | 2008-03-19 | 贝林格尔·英格海姆国际有限公司 | Cgrp拮抗剂、其制备方法以及其作为药物的用途 |
| US7439237B2 (en) * | 2005-04-15 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| DE102005038831A1 (de) * | 2005-08-17 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7834007B2 (en) * | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| EP1770086A1 (de) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| DE102005050892A1 (de) * | 2005-10-21 | 2007-04-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| ES2433251T5 (es) | 2005-11-14 | 2020-03-13 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos |
| DE102006017827A1 (de) | 2006-04-13 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue kristalline Verbindungen |
| PE20080153A1 (es) * | 2006-06-08 | 2008-04-14 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp) |
| JP5335228B2 (ja) * | 2006-12-27 | 2013-11-06 | キヤノン株式会社 | 新規化合物および有機半導体素子の製造方法 |
| EP2065381A1 (de) | 2007-10-18 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP Antagonisten |
| EP2205599B1 (de) | 2007-10-18 | 2012-06-06 | Boehringer Ingelheim International GmbH | Cgrp-antagonisten |
| US8829006B2 (en) | 2007-11-22 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Compounds |
| BRPI0908276B8 (pt) | 2008-03-04 | 2021-05-25 | Labrys Biologics Inc | uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite |
| RU2522493C2 (ru) | 2008-03-04 | 2014-07-20 | Пфайзер Лимитед | Способы лечения хронической боли |
| KR101519192B1 (ko) | 2009-08-28 | 2015-05-11 | 리나트 뉴로사이언스 코프. | 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법 |
| AU2012258980B8 (en) | 2011-05-20 | 2017-06-15 | H. Lundbeck A/S | Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| US9855332B2 (en) * | 2011-05-20 | 2018-01-02 | Alderbio Holdings Llc | Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels |
| TWI646111B (zh) | 2011-05-20 | 2019-01-01 | 艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）組成物及其用途 |
| JPWO2016199688A1 (ja) * | 2015-06-10 | 2018-03-29 | 住友化学株式会社 | カーバメート化合物の製造方法 |
| GB201519196D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| JP2022516956A (ja) | 2019-01-08 | 2022-03-03 | ハー・ルンドベック・アクチエゼルスカベット | 抗ｃｇｒｐ抗体を用いた頭痛の急性治療及び迅速治療 |
| CN113655035B (zh) * | 2021-08-12 | 2024-06-28 | 深圳上泰生物工程有限公司 | 一种糖缺失性转铁蛋白分离方法及检测方法与试剂盒 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US665378A (en) * | 1900-06-15 | 1901-01-01 | William James Mcmurtry | Manufacture of self-igniting gas mediums. |
| TW209870B (es) * | 1990-01-18 | 1993-07-21 | Pfizer | |
| US5442044A (en) * | 1991-01-04 | 1995-08-15 | Pfizer Inc. | Orally active renin inhibitors |
| JP3483893B2 (ja) | 1996-09-10 | 2004-01-06 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 修飾アミノ酸、これらの化合物を含む薬物及びそれらの調製方法 |
| DE19911039A1 (de) * | 1999-03-12 | 2000-09-14 | Boehringer Ingelheim Pharma | Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US6653478B2 (en) * | 2000-10-27 | 2003-11-25 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators |
| AU2003237255B8 (en) * | 2002-06-05 | 2010-01-07 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| DE10300973A1 (de) * | 2003-01-14 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| EP1722792A1 (de) * | 2004-03-03 | 2006-11-22 | Boehringer Ingelheim International GmbH | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
| DE102004015723A1 (de) * | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7547694B2 (en) * | 2004-04-15 | 2009-06-16 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| DE102004018795A1 (de) | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE102004018794A1 (de) | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7279471B2 (en) * | 2004-04-15 | 2007-10-09 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| DE102004019492A1 (de) | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7696195B2 (en) * | 2004-04-22 | 2010-04-13 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| EP1770091A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7491717B2 (en) * | 2005-03-23 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| CN101146799A (zh) | 2005-03-23 | 2008-03-19 | 贝林格尔·英格海姆国际有限公司 | Cgrp拮抗剂、其制备方法以及其作为药物的用途 |
| US7439237B2 (en) * | 2005-04-15 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| DE102005038831A1 (de) | 2005-08-17 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| EP1770087A1 (de) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| EP1770086A1 (de) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE102005050892A1 (de) | 2005-10-21 | 2007-04-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
-
2002
- 2002-10-25 DE DE10250082A patent/DE10250082A1/de not_active Withdrawn
-
2003
- 2003-10-15 US US10/685,921 patent/US20040132716A1/en not_active Abandoned
- 2003-10-23 WO PCT/EP2003/011763 patent/WO2004037811A1/de active Application Filing
- 2003-10-23 MX MXPA05004188A patent/MXPA05004188A/es unknown
- 2003-10-23 PL PL03376373A patent/PL376373A1/xx not_active Application Discontinuation
- 2003-10-23 CA CA002503462A patent/CA2503462A1/en not_active Abandoned
- 2003-10-23 KR KR1020057007157A patent/KR20050083821A/ko not_active Application Discontinuation
- 2003-10-23 BR BR0315642-7A patent/BR0315642A/pt not_active Expired - Fee Related
- 2003-10-23 JP JP2004545964A patent/JP4435687B2/ja not_active Expired - Fee Related
- 2003-10-23 CN CNA2003801019804A patent/CN1708492A/zh active Pending
- 2003-10-23 RS YUP-2005/0329A patent/RS20050329A/sr unknown
- 2003-10-23 UA UAA200504875A patent/UA82206C2/uk unknown
- 2003-10-23 ME MEP-514/08A patent/MEP51408A/xx unknown
- 2003-10-23 EA EA200500601A patent/EA009984B1/ru not_active IP Right Cessation
- 2003-10-23 AU AU2003276157A patent/AU2003276157A1/en not_active Abandoned
- 2003-10-23 EP EP03809318A patent/EP1558601A1/de not_active Withdrawn
- 2003-10-23 PE PE2003001078A patent/PE20040780A1/es not_active Application Discontinuation
- 2003-10-24 TW TW092129585A patent/TW200427681A/zh unknown
- 2003-10-24 UY UY28040A patent/UY28040A1/es not_active Application Discontinuation
- 2003-10-24 AR ARP030103890A patent/AR043056A1/es not_active Suspension/Interruption
-
2005
- 2005-03-17 ZA ZA200502247A patent/ZA200502247B/xx unknown
- 2005-04-22 HR HR20050365A patent/HRP20050365A2/hr not_active Application Discontinuation
- 2005-04-25 EC EC2005005746A patent/ECSP055746A/es unknown
- 2005-05-24 NO NO20052493A patent/NO20052493D0/no not_active Application Discontinuation
- 2005-05-24 CO CO05050510A patent/CO5570703A2/es not_active Application Discontinuation
-
2007
- 2007-06-04 US US11/757,743 patent/US7700589B2/en not_active Expired - Lifetime
-
2010
- 2010-02-17 US US12/706,840 patent/US20100152171A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05004188A (es) | 2005-10-05 |
| CA2503462A1 (en) | 2004-05-06 |
| KR20050083821A (ko) | 2005-08-26 |
| TW200427681A (en) | 2004-12-16 |
| CN1708492A (zh) | 2005-12-14 |
| JP2006505573A (ja) | 2006-02-16 |
| ECSP055746A (es) | 2005-07-06 |
| EA009984B1 (ru) | 2008-04-28 |
| BR0315642A (pt) | 2005-08-30 |
| JP4435687B2 (ja) | 2010-03-24 |
| NO20052493L (no) | 2005-05-24 |
| RS20050329A (en) | 2007-08-03 |
| US20100152171A1 (en) | 2010-06-17 |
| MEP51408A (en) | 2011-02-10 |
| ZA200502247B (en) | 2005-09-19 |
| EA200500601A1 (ru) | 2006-02-24 |
| US7700589B2 (en) | 2010-04-20 |
| WO2004037811A1 (de) | 2004-05-06 |
| UY28040A1 (es) | 2004-05-31 |
| EP1558601A1 (de) | 2005-08-03 |
| PL376373A1 (en) | 2005-12-27 |
| US20040132716A1 (en) | 2004-07-08 |
| AU2003276157A1 (en) | 2004-05-13 |
| HRP20050365A2 (en) | 2006-05-31 |
| UA82206C2 (uk) | 2008-03-25 |
| NO20052493D0 (no) | 2005-05-24 |
| WO2004037811A8 (de) | 2005-05-19 |
| AR043056A1 (es) | 2005-07-13 |
| DE10250082A1 (de) | 2004-05-13 |
| US20070244099A1 (en) | 2007-10-18 |
| PE20040780A1 (es) | 2005-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5570703A2 (es) | Antagonistas de cgrp elegidos, procedimiento para su prepara cion, asi como su empleo como medicamentos | |
| CO5570704A2 (es) | Antagonistas de cgrp elegidos, procedimiento para su prepara cion, asi como su empleo como medicamentos | |
| AR053329A1 (es) | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) | |
| AR077817A1 (es) | Derivados de 1, 2, 4-triazol y su uso como pesticidas | |
| RU2485104C2 (ru) | Новые производные 1,2-дигидрохинолина, обладающие активностью связывания глюкокортикоидного рецептора | |
| AR074596A1 (es) | Derivados de (3-oxo) piridazin-4-ilurea | |
| AR049625A1 (es) | Antagonistas de cgrp, procedimiento para su preparacion asi como su uso como medicamento | |
| AR049422A1 (es) | Antagonistas de cgrp seleccionados, procedimiento para su preparacion asi como su uso como medicamento | |
| PE20160859A1 (es) | Inhibidores de la quinasa reguladora de la senal de apoptosis | |
| AR039569A1 (es) | Piperidinas sustituidas, medicamentos que contienen estos compuestos y procedimientos para su preparacion | |
| AR070636A1 (es) | Derivados de piridina, composicion farmaceutica y uso terapeutico | |
| PE20060334A1 (es) | Derivados de piridina como antagonistas del receptor a2b de adenosina | |
| AR074902A1 (es) | Derivados de 1,2,4-oxadiazoles agonistas de receptores s1p1 | |
| ES2503570T3 (es) | Conjugado del factor de coagulación sanguíneo VIIA y PEG | |
| PE20110294A1 (es) | Compuestos heterociclicos como inhibidores de enzimas de senal especifica | |
| CO6260001A2 (es) | Combinaciones de principios activos que contienen un compuesto de aminofurano y un compuesto de neonicotinoides | |
| CL2011001333A1 (es) | Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
| AR048669A1 (es) | Derivados biciclicos de bisamida | |
| AR015765A1 (es) | Dihidropirimidinas 2 heterociclicamente sustituidas, proceso para su preparacion, medicamentos que los contienen, proceso para la preparacion de los mismosuso de dichos dihidropirimidinas para la preparacion de un medicamento. | |
| RU2014117207A (ru) | 5-фторпиримидиновые производные в качестве фунгицидов | |
| DE602006018152D1 (de) | Triazolderivate als modulatoren von dopamin-d3-rezeptoren | |
| AR062125A1 (es) | Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos | |
| ES2563317T3 (es) | Pirrolidinonas como inhibidores de MetAP-2 | |
| PE20030200A1 (es) | Bencimidazol como inhibidores de las map quinasas | |
| EA200870404A1 (ru) | Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |